postpartum-header.jpg

Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
 
 
NASDAQ: MRNS
*Delayed quote courtesy of Google Finance.

View Stock Information







Events & Presentations

View All Events & Presentations